吉利德停止研发瑞德西韦

牛唐

2021-07-31

$吉利德科学(GILD)$ 已决定停止其COVID-19治疗药物remdesivir的吸入制剂的临床开发。

Gilead首席执行官Daniel O'Day周四在公司2021年第二季度财报公布后的电话会议上表示，该决定基于一项概念验证研究的数据，该研究表明该药物在肺部的累积量低于标准，

Remdesivir，也称为Veklury，是FDA批准的第一种COVID-19的抗病毒药物。吉利德公司2021年第二季度Remdesivir的销售额为8.29亿美元，大大低于上一季度的15亿美元。

$蔚来(NIO)$ $游戏驿站(GME)$ $fuboTV Inc.(FUBO)$ $Skillz Inc(SKLZ)$

下一个美股打新，会是大肉签吗？

药明康德、红杉资本等投资的天演药业和SaaS第一中概股容联云将在本月上市，2020年上市的中概股表现优异，这两家你看好吗？

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

牛唐
2021-08-05
牛唐
这个和国内的药企不一样，不喜欢吹嘘
这是技术性调整
2021-07-31
这是技术性调整
不了解

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":806751279,"tweetId":"806751279","gmtCreate":1627695908391,"gmtModify":1627697374661,"author":{"id":3452938437060827,"authorId":3452938437060827,"authorIdStr":"3452938437060827","name":"牛唐","avatar":"https://static.tigerbbs.com/de2e2f2e2676bc8463b050f4e3ff17d2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[{"themeId":"3dedd76b82b147d9878afe8793c4b4c8","categoryId":"7ba93224048e4975aa9a5a60d7f2353b","name":"下一个美股打新，会是大肉签吗？","type":3,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/special/discussion&rndata={\"themeId\":3dedd76b82b147d9878afe8793c4b4c8}&rnconfig={\"headerBarHidden\": true}","description":"药明康德、红杉资本等投资的天演药业和SaaS第一中概股容联云将在本月上市，2020年上市的中概股表现优异，这两家你看好吗？","image":"https://static.tigerbbs.com/109478ac79e7b1010aba611ffde0b0b2"}],"images":[],"coverImages":[],"title":"吉利德停止研发瑞德西韦","extraTitle":"","html":"<html><head></head><body><a target=\"_blank\" href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>&nbsp;已决定停止其COVID-19治疗药物remdesivir的吸入制剂的临床开发。Gilead首席执行官Daniel O'Day周四在公司2021年第二季度财报公布后的电话会议上表示，该决定基于一项概念验证研究的数据，该研究表明该药物在肺部的累积量低于标准，Remdesivir，也称为Veklury，是FDA批准的第一种COVID-19的抗病毒药物。吉利德公司2021年第二季度Remdesivir的销售额为8.29亿美元，大大低于上一季度的15亿美元。<a target=\"_blank\" href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/SKLZ\">$Skillz Inc(SKLZ)$</a>&nbsp;</body></html>","htmlText":"<html><head></head><body><a target=\"_blank\" href=\"https://laohu8.com/S/GILD\">$吉利德科学(GILD)$</a>&nbsp;已决定停止其COVID-19治疗药物remdesivir的吸入制剂的临床开发。Gilead首席执行官Daniel O'Day周四在公司2021年第二季度财报公布后的电话会议上表示，该决定基于一项概念验证研究的数据，该研究表明该药物在肺部的累积量低于标准，Remdesivir，也称为Veklury，是FDA批准的第一种COVID-19的抗病毒药物。吉利德公司2021年第二季度Remdesivir的销售额为8.29亿美元，大大低于上一季度的15亿美元。<a target=\"_blank\" href=\"https://laohu8.com/S/NIO\">$蔚来(NIO)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/GME\">$游戏驿站(GME)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/FUBO\">$fuboTV Inc.(FUBO)$</a>&nbsp;<a target=\"_blank\" href=\"https://laohu8.com/S/SKLZ\">$Skillz Inc(SKLZ)$</a>&nbsp;</body></html>","text":"$吉利德科学(GILD)$ 已决定停止其COVID-19治疗药物remdesivir的吸入制剂的临床开发。 Gilead首席执行官Daniel O'Day周四在公司2021年第二季度财报公布后的电话会议上表示，该决定基于一项概念验证研究的数据，该研究表明该药物在肺部的累积量低于标准， Remdesivir，也称为Veklury，是FDA批准的第一种COVID-19的抗病毒药物。吉利德公司2021年第二季度Remdesivir的销售额为8.29亿美元，大大低于上一季度的15亿美元。 $蔚来(NIO)$ $游戏驿站(GME)$ $fuboTV Inc.(FUBO)$ $Skillz Inc(SKLZ)$","highlighted":1,"essential":1,"paper":2,"likeSize":31,"commentSize":5,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/806751279","repostId":0,"isVote":1,"tweetType":1,"viewCount":7881,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["GILD","NIO","FUBO","SKLZ","GME"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":433,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":5432355,"gmtCreate":1628133693496,"gmtModify":1628133693496,"authorId":3452938437060827,"author":{"id":3452938437060827,"authorId":3452938437060827,"name":"牛唐","avatar":"https://static.tigerbbs.com/de2e2f2e2676bc8463b050f4e3ff17d2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806751279,"type":1,"supId":0,"prevId":0,"content":"这个和国内的药企不一样，不喜欢吹嘘","text":"这个和国内的药企不一样，不喜欢吹嘘","html":"这个和国内的药企不一样，不喜欢吹嘘","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0},{"id":5387797,"gmtCreate":1627722890411,"gmtModify":1627722890411,"authorId":3575499707386483,"author":{"id":3575499707386483,"authorId":3575499707386483,"name":"这是技术性调整","avatar":"https://static.tigerbbs.com/34eadfd257f4edca2c3b49f50372da51","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":806751279,"type":1,"supId":0,"prevId":0,"content":"不了解","text":"不了解","html":"不了解","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/806751279"}